Kraig Biocraft Laboratories, Inc. (Trading Symbol: KBLB) is a fully reporting biotechnology company focused on the development and commercialization of spider silks. As a reporting company, our annual and quarterly reports to the SEC can be found on EDGAR and on this website. Our investments in genetic research are targeted for product development and innovative near-term solutions to meet the practical problems of our world.
Our genetic engineering research has succeeded in developing what many considered to be the holy grail of material science: A practical and cost-effective technology for producing recombinant spider silk based fibers on an industrial scale. We are moving rapidly to commercialize our spider silk technology, which we believe will have a significant impact on the global textiles industry. At the same time we are continuing to work in cooperation with leading laboratories to create new stronger and more flexible spider silk based fibers with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for textiles and performance polymers.
At Kraig, we are passionate about pioneering the research, development and commercialization of the next generation of high performance fibers based on genetic engineered spider silk. We are the world leader in our field of genetic research and product development.
Kraig Biocraft Laboratories, Inc. (Trading Symbol: KBLB) is an innovative and aggressive biotechnology company focused on the development and commercialization of spider silk. Based on proprietary genetic engineering technology, Kraig Labs has successfully developed and produced next-generation polymers and protein-based fibers including recombinant spider silk. Our work has recently succeeded in creating and developing new fibers that have never been seen before with extraordinary properties of strength and flexibility. Our research arm remains focused on the continued development of new recombinant spider silks and other high strength polymers that we believe have the potential for significant industrial and consumer applications. In 2016, Kraig Biocraft Labs was awarded its first U.S. Army contract, with whom we hope to help produce the next generation in soldier protective equipment.